Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Oil Prices Slip as U.S.–Iran Talks Ease Supply Disruption Fears 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Asian Currencies Trade Sideways as Dollar Stabilizes, Yen Weakens Ahead of Japan Election 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
